ADMA ADMA Biologics Inc

3.95
+0.05  (+1%)
Previous Close 3.9
Open 3.9
Price To Book 5
Market Cap 234,305,334
Shares 59,317,806
Volume 625,822
Short Ratio
Av. Daily Volume 784,116

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced April 1, 2019.
RI-002
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)
  2. ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
  3. ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
  4. Did ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Buy Up More Shares?
  5. How Many ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Did Insiders Buy, In The Last Year?
  6. ADMA Biologics: Selloff Creates Buying Opportunity
  7. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  8. ADMA Biologics Is De-Risked and Ready to Rise
  9. ADMA Biologics to Present at Upcoming Investor Conferences
  10. These 3 Biotech Stocks Are Attracting Insider Buying
  11. ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  12. Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares
  13. NeuBase Therapeutics Designates Industry Leaders to Board of Directors 
  14. ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock
  15. FDA Approves Prior Approval Supplement for BIVIGAM®
  16. Adma Biologics: 1Q Earnings Snapshot
  17. ADMA Biologics Reports First Quarter 2019 Financial Results
  18. ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
  19. ADMA Biologics: Wall Street Projects Robust Revenue Growth